Assembly Biosciences appoints Gilead designee to board, adopts 2024 bonus plan

ASSEMBLY BIOSCIENCES, INC.

Robert D. Cook II, Gilead's VP of Risk Governance and Audit, appointed to Board as Gilead designee per Oct 15, 2023 Investor Rights Agreement; no compensation.
Compensation Committee approved 2024 Corporate Bonus Plan effective Jan 1 2024 with cash bonuses tied to corporate and individual objectives.
CEO bonus target up to 75% of base salary; other executive participants 30-55%; non-executive participants up to 28%.
Cash bonuses range from 0 to 1.5x target; paid by March 15 following performance year; employment through payment date required.
Weighting: CEO 100% corporate; C-Level/SVP 75/25; VP/Exec Dir/Sr Dir 50/50; below Sr Dir 25/75.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Robert D. Cook II

Director

ASMB · ASSEMBLY BIOSCIENCES, INC.

Effective: 2024-03-13
Filed: March 15, 2024, 7:59 PM ET

On March 13, 2024, the Board appointed Robert D. Cook II, a designee of Gilead Sciences, Inc. ("Gilead"), to serve on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert D. Cook II was appointed as Director at ASSEMBLY BIOSCIENCES, INC..

Action: appointed
Role: Director

Exact text from the filing

On March 13, 2024, the Board appointed Robert D. Cook II, a designee of Gilead Sciences, Inc. ("Gilead"), to serve on the Board.

View on SEC.gov

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-032162

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.